在家族性高密度胆固醇缺乏与缺陷胆固醇外流的ABC1基因突变
M Marcil1, A Brooks-Wilson, S M Clee
1Xenon Bioresearch Inc, NRC Innovation Centre, Vancouver, British Columbia, Canada.
Lancet (London, England)
|October 26, 1999
概括
在ATP结合盒 (ABC1) 基因的突变导致家族高密度脂蛋白 (HDL) 缺乏通过损害细胞胆固醇流动. 这突出了ABC1调制作为提高高脂水平的潜在策略.
科学领域:
- 遗传学和分子生物学
- 心血管研究研究心血管研究
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 低高密度脂蛋白 (HDL) 胆固醇在早产动脉样硬化中很常见.
- 坦吉尔病是一种严重的HDL缺乏症,由ATP结合盒 (ABC1) 基因的突变引起,该基因编码胆固醇流量调节蛋白 (CERP).
研究的目的:
- 在患有家族性HDL缺乏症的患者中研究ABC1基因突变.
主要方法:
- 研究了三个法国加拿大家庭和一个荷兰家庭的家族性HDL缺乏症.
- 分析了纤维细胞胆固醇外流,并对ABC1基因的编码区域进行了测序.
- 使用PCR和RFLP测试来追踪家族内和对照中的突变.
主要成果:
- 在每个家族中确定了不同的ABC1突变,导致CERP截断或改变氨基酸残留.
- 所有发现的突变与低水平的HDL胆固醇分离.
- 在500多个控制染色体中没有发现突变.
结论:
- ABC1突变是家族性HDL缺乏的主要原因,与受损胆固醇排泄有关.
- 在HDL形成中,CERP起着至关重要的作用.
- 调节ABC1提供了一种潜在的治疗方法,以增加HDL度.
相关概念视频
ABC Transporters: Exporter
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
ABC Transporters: Importer
ATP-binding cassette or ABC transporters are a class of ATP-driven pumps that hydrolyze ATP to move solutes across the membrane. They can be grouped into importers and exporters. While exporters are present in all domains of life, importers exist only in bacteria and some plants.
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


